Login to Your Account



Clinic Roundup


Friday, April 22, 2011
Marinus Pharmaceuticals Inc., of Branford, Conn., announced the start of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of post-traumatic stress disorder (PTSD). The company said that ganaxolone modulates inhibitory GABA-A receptors, possibly at a specific neurosteroid recognition site. Neurosteroid levels have been implicated in both the severity and treatment outcome in PTSD patients. The trial will take place in the U.S. and is expected to enroll about 120 PTSD patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription